
Cantargia Q3 2024 - IL1RAP Companion Diagnostic Next

Redeye comments on Cantargia's Q3 report, the proposed rights issue of SEK170m and the plans to focus on IL1RAP-high patients.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cantargia Q3 2024 - IL1RAP Companion Diagnostic Next](#)